Lmcg Investments LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lmcg Investments LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,371 shares of the biopharmaceutical company’s stock after selling 453 shares during the period. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $3,114,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of REGN. Aspiriant LLC grew its position in shares of Regeneron Pharmaceuticals by 14.5% in the 4th quarter. Aspiriant LLC now owns 387 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 49 shares during the last quarter. Crossmark Global Holdings Inc. lifted its stake in Regeneron Pharmaceuticals by 3.6% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company’s stock worth $1,890,000 after acquiring an additional 92 shares during the period. Cove Private Wealth LLC bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $313,000. Willner & Heller LLC increased its position in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 15 shares during the period. Finally, Mechanics Bank Trust Department bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $288,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on REGN. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Bank of America reaffirmed an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $681.58 on Tuesday. The business has a 50-day simple moving average of $738.60 and a two-hundred day simple moving average of $948.80. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.61 and a beta of 0.10.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.